Silence Therapeutics announced that it has completed enrollment in the ALPACAR-360 phase 2 study of zerlasiran in subjects with elevated lipoprotein at high risk of atherosclerotic cardiovascular disease, or ASCVD, events.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on SLN:
- Silence announces publication demonstrating role for iron regulation in PV
- Virpax Pharmaceuticals appoints Ruskin to board of directors
- Silence Therapeutics to buyback siRNA complement assets
- Silence Therapeutics appoints Romano as Incoming Chief Medical Officer
- Silence Therapeutics price target lowered to $26 from $29 at Chardan
